XPhyto Therapeutics Hugh Rogers talks about rapid-results virus testing
InvestorIntel’s Peter Clausi talks with Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. (CSE: XPHY | OTCQB: XPHYF) about XPhyto’s COVID-19 testing program. “Our goal was to develop a test that could produce results in less than 15 minutes, and we are now, in lab, generating results in less than 5 minutes,” Hugh said. “We have an enhanced probe system that does not require equipment. Our detection is capable of detecting the virus within the full range of infection – that is, pre-symptomatic, asymptomatic as well as on the tail end of an infection.”
Hugh went on to say, “We have drug development platforms and a number of programs. We are more diversified than just a testing company.” He added that their “lead program on the transdermal side is a Parkinson’s generic called Rotigotine, a slow release patch, and our lead program on the oral dissolvable side is CBD based for epilepsy. It is many times more efficient than an oil-based system. It is faster. It is more predictable.”
To watch the complete interview, click here
Disclaimer: XPhyto Therapeutics Corp. is an advertorial member of InvestorIntel Corp.
Raj Shah has professional experience working for over a half a dozen years at financial firms such as Merrill Lynch and First Allied Securities Inc., ... <Read more about Raj Shah>